IRISH MEDICINES BOARD

news MEDICINAL PRODUCTS LETTER

JANUARY – JUNE 2005 Issue No. 20

IRISH MEDICINES BOARD, KEVIN O'MALLEY HOUSE, EARLSFORT CENTRE, EARLSFORT TERRACE, DUBLIN 2 TEL: 01 676 4971 FAX: 01 6767836 EMAIL: FOI@IMB.IE

GENERAL

IMB Headquarters named Kevin O'Malley House

The IMB has dedicated its headquarters to Professor Kevin O'Malley in honour of his outstanding commitment and dedication to the field of medicines regulation in Ireland. Professor O'Malley served as a board member of the IMB and its predecessor the National Drugs Advisory Board (NDAB) for some 27 years. An Tánaiste, Mary Harney T.D., performed the official dedication ceremony at the IMB's offices on Earlsfort Terrace.

The IMB's premises are now named Kevin O'Malley House. Professor O'Malley served the NDAB as a member of the Committee and Board from 1977 to 1995. He was Chairman of the NDAB from 1985 to 1995. He served as a Board member and Chairman of the Advisory Committee for Human Medicines of the IMB from 1996 to his retirement in 2004.

Speaking at the occasion, Pat O'Mahony, Chairman of the IMB, paid tribute to Professor O'Malley for his long dedicated service to the Irish medical arena and the enormous contribution he made to progress in the medicines regulatory environment for the benefit of public health.

'Professor O'Malley has shown extraordinary commitment to the NDAB and IMB during his career. He provided expert advice not only in his specialised area of medicines but also in respect of other policy and business matters. His contributions were extremely valuable to the collective thinking of the Board. He played a key role in progressing and expanding the organisation since its foundation, to its position today as a key national driving force in protecting public health through continuous, effective and efficient control of medicines and medical devices. The

The Irish Medicines Board has officially dedicated the Irish Medicines Board Headquarters on Earlsfort Terrace to Professor Kevin O'Malley to mark his long standing contribution to the Irish medical arena. Professor Kevin O'Malley (centre) is presented with the plaque by Pat O'Mahony, Chief Executive of the Irish Medicines Board (left) and An Tanaiste and Minister for Health and Children, Mary Harney, TD (right).

CONTENTS

The Irish Medicines Board officially dedicated the Irish Medicines Board Headquarters on Earlsfort Terrace to Professor Kevin O'Malley. Pictured at the official naming ceremony of the building as Kevin O'Malley House are (l-r) Pat O'Mahony, Chief Executive of the Irish Medicines Board, An Tanaiste and Minister for Health and Children, Mary Harney, TD, and Pat O'Mahony, Chairman of the Irish Medicines Board.

IMB is recognised nationally and internationally as a centre of excellence for both the quality and scientific rigour it brings to its work and quality of outputs. On behalf of the IMB Board and its staff we thank Prof O'Malley for his participation in our organisation and wish him well in his future ambitions,' stated Mr O'Mahony.

STAFF CHANGES

Carol Fitzpatrick was appointed Scientific Officer in the Human Medicines Department.

Joseph Gallagher was appointed Vigilance Officer in the Medical Devices Department.

Peter Kiely and *Tom Ryle* were appointed Medical Officers in the Human Medicines Department.

Niall McAllenan was appointed Medical Officer in the Medical Devices Department.

Anne Hayes was appointed Inspection Manager in the Compliance Department.

Kevin O'Donnell was appointed Market Compliance Manager in the Compliance Department.

HUMAN MEDICINES

LEGISLATION AND GUIDELINES

The following EU guidelines have been adopted.

Clinical guidelines

CPMP/BPWG/2231/99 Core SPC for Human Albumin Solution Revision 1

EMEABWP/125/04 Guideline on Epidemiological Data on Blood Transmissible Infections (CHMP adopted January 2005)

CHMP/EWP/191583/05 Questions and Answers document on the Clinical Development of Fixed Combinations of Drugs Belonging to Different Therapeutic Classes in the Field of Cardiovascular Treatment and Prevention (CHMP adopted June 2005)

CPMP/EWP/552/95 Revision 2 Recommendation on the need for Revision of CHMP Note for Guidance on Post-Menopausal Osteoporosis in Women

CPMP/EWP/2339/02 Guideline on Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impairment Hepatic Function (CHMP adopted February 2005)

CPMP/EWP/4279/02 Guideline on Clinical Investigation of Medicinal Products for the Treatment of Obsessive Compulsive Disorder (CHMP adopted January 2005)

CPMP/EWP/4280/02 Guideline on the Clinical Investigation of Medicinal Products indicated for the Treatment of Panic Disorder (CHMP adopted January 2005)

CPMP/EWP/4284/02 Guideline on the Clinical Investigation of Medicinal Products indicated for Generalised Anxiety Disorder (CHMP adopted January 2005)

CHMP/ICH/2/04 The Clinical Evaluation of QT/QTs Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic drugs (CHMP adopted May 2005)

Non-clinical guidelines

CPMP/SWP/1094/04 Guideline on the Evaluation of Control Samples for Nonclinical Safety Studies: Checking for Contamination with the Test Substance (CPMP adopted March 2005)

Quality guidelines

CPMP/QWP/576/96 - Rev. 1 (also CVMP/373/04) Guideline on Stability Testing for Applications for Variations to a Marketing Authorisation (Adopted by CHMP/CVMP, April/May 2005)

CPMP/QWP/4539/03 Guideline on Plastic Primary Packaging Materials (Adopted by CHMP/CVMP, April/May 2005)

Regulatory guidelines

EMEA/P/24143/04 Procedure for European Union Guidelines and Related Documents within the Pharmaceutical Legislative Framework (EMEA adopted June 2005)

CPMP/328/98 Rev. 4 Guideline on the Acceptability of Invented names for Medicinal Products processed

through the Centralised Procedure (CHMP Adopted April 2005)

Notice to Applicants

Part 1A / CTD Module 1 - Administrative information: application form and User Guide for the Application Form

Application form for renewal of a marketing authorisation

Volume 2A Chapter 7 General Information

Guideline on the packaging information of medicinal products for human use authorised by the Community (April 2005)

Clinical trials

Commission directive 2005/28/EC of 8 April 2005 on good clinical practice

Guideline on the data fields from the European clinical trials database (EudraCT) that may be included in the European database on Medicinal Products

Revised 'Question and Answer' document for clinical trials

European Court of Justice judgement on the procedure for generic medicinal products

In a judgment of 20 January 2005, the European Court of Justice has ruled that an application for a marketing authorisation under the abridged procedure of Article 10(1)(a)(iii) of Directive 2001/83/EC may be made for a generic product claiming to be 'essentially similar' to a reference product, where that product contains the same therapeutic moiety as the reference product but combined with another salt. According to the Court, such a difference cannot normally prevent two medicinal products from being regarded as essentially similar, unless it appears that the generic product shows significant differences from the original product as regards safety and efficacy.

HUMAN MEDICINES INFORMATION DAY

The IMB will host a Human Medicines Information Day on 14 October 2005 in the Great Southern Hotel, Dublin Airport. The meeting will commence at 9.00am and will end at 3.30pm approximately. The main topic of the meeting will be the implementation of the new medicines legislation with items on the Coordination Group; legal basis and data exclusivity; renewals and sunset clause; key changes affecting manufacturers and wholesalers; product information; pharmacovigilance and extranet services. For registration information please refer to the Human Medicines Event section of the IMB website.

NEW MEDICINES LEGISLATION DIRECTIVE 2004/27/EEC, 2004/24/EC

The guidance in this section is based on the IMB's current understanding of the new requirements, which are the subject of on-going discussion at EU level. Arising from these discussions, existing EU guidance documents and forms are undergoing revision and new documents are being drafted. Companies are advised to check the EMEA, EU Commission and MRFG websites regularly over the coming months for updates and further information. Further IMB guidance will be published when these discussions have concluded and EU guidance and forms are published.

The guidance below applies to nationally-authorised products. For products within mutual-recognition, please also see the guidance on the MRFG website. For products authorised via the centralised procedure, please see the guidance on the EMEA website.

Definition of a Medicinal Product

Article 1 of Directive 2004/27/EC makes changes to the definition of a medicinal product, as currently given in Article 1(2) of EC Directive 2001/83/EC. The new definition states that to be a medicine the product must be:

(i) Any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or

(ii) Any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.

A new provision has been added to Article 2. Article 2(2) of Directive 2001/83/EC as amended now states that:

'In cases of doubt, where taking into account all its characteristics, a product may fall within the definition of a product covered by other Community legislation the provisions of this Directive shall apply.'

Taken together, these provisions are intended to ensure that, where doubt exists over whether a product – those on the 'borderline' between, for example, medicines and medical devices, medicines and cosmetics, medicines and food supplements etc – should be regulated under medicines or other sectoral legislation, the stricter medicines regulatory regime should apply.

Further, point 20 of Article 1, in which an explanation is provided of the name given to a medicinal product, has also been revised to state that the name 'may be either an invented name not liable to confusion with a common name or common or scientific name accompanied by a trademark or the name of the marketing authorisation holder'.

While the impact on conventional medicinal products and medical devices is not expected to be extensive, it is important to be aware of such changes. There may however be some products on the borderline between medical products and medical devices which will need to be re-categorised following the implementation of the revised legislation.

These changes are due to be made effective from the beginning of November 2005. The IMB 'Guide to the Definition of a Medicinal Product' is consequently under revision to reflect these and other changes arising from updates to the legislation. This will also include the clearer statement in Article 2(2) that where there is any doubt in regard to products which may fall on the borderline

between medicinal and other legislative categories, the medicines legislation takes priority. The revised IMB guideline will be published for consultation during September.

New applications for authorisations

All new applications submitted to the IMB after 30 October 2005 for a national authorisation or through the mutual-recognition or decentralised procedures must comply with the new requirements. Applicants should ensure that they submit the required information in line with updates given on the EU Commission and MRFG websites.

Applications for variations to existing authorisation

The general procedures for variations are not affected by the new medicines legislation. However specific guidance may be provided for particular variations which may be affected by the new requirements. Applicants should ensure they have the latest information from the EU Commission's website and the website of the MRFG.

Article 23 of Directive 2004/27/EC requires the authorisation holder to submit any new information which might amend the application documents, any information on prohibitions or restrictions in another country and any new information which might influence the benefits and risks of the product. All such information must be submitted as a variation application.

Renewals of existing marketing authorisations

The IMB's requirements in relation to renewals of product authorisations for medicinal products for human use are outlined below. In essence, the IMB will require one further renewal under the new directive for all existing authorisations.

Authorisations which have an expiry date before or on 30 October 2005

Applications should be made according to the current requirements outlined on the IMB website (**www.imb.ie**). The renewed authorisations will be issued under the current legislation and will be valid for a five-year period. These authorisations will undergo a further renewal under the new legislation by 30 October 2010.

Authorisations which have an expiry date after 30 October 2005

- *Timing*
  Applications for authorisations which are due for renewal between 31 October 2005 and 30 April 2006 should be submitted at least three months in advance. Applications for authorisations which are due for renewal from 1 May 2006 must be submitted six months before the expiry date.

- *Applications*
  Applications must include the EU renewal application form and the IMB form for additional national requirements, and all documents required by these forms. Both forms will be updated in line with the new requirements. At the time of printing, the IMB does not have an expected date of revision for the EU form; the IMB form will be revised once the revised EU form is available. Applicants should continue to use the current forms until such time as the new forms are published. The following requirements should also be noted:

  - Periodic Safety Update Reports are an integral part of the renewal process and will continue to be required in support of renewal applications.
  - Under Article 46f of Directive 2004/27/EC, manufacturers of finished products are obliged to use active substances made under conditions of GMP. The renewal application must include declarations that the active substance manufacturer(s) operate in compliance with the detailed guidance on GMP for starting materials. Further guidance on the declarations is awaited from the relevant EU working parties.

- *Renewed authorisations*
  The renewed authorisation will be valid for an indefinite period. However a second renewal may be required for pharmacovigilance reasons. In these cases, the renewed authorisation will be valid for a five-year period.

Product information (SPC, label and leaflet)

The new legislation includes changes to:

- format of the SPC for radiopharmaceutical products
- content of labels
- content and format of package leaflets
- user consultation for package leaflets

Authorisations granted before 30 October 2005

Products which are currently authorised should comply with the new requirements by 30 October 2010 at the latest. The update may be done at the time of renewal of the product authorisation (so long as the changes are clearly outlined in the application) or by the submission of a variation application.

Authorisations granted after 30 October 2005

New products authorised after 30 October 2005 must comply with the new requirements for the SPC, label and leaflet.

Additional guidance on Braille and on package leaflets for persons with visual impairment

The requirements for Braille on outer packaging and for package leaflets for persons with visual impairment are set out in the EU Commission's guidance document, as indicated in the last IMB newsletter. Compliance with these requirements will be based on a signed declaration from the applicant, and market compliance monitoring. A declaration form will be available on the IMB website by September.

Sunset clause

The sunset clause (Article 24.4 of Directive 2004/27/EC) will be applied to all products after 30 October 2005. Under these provisions, a product

authorisation ceases to be valid if the product has not been marketed for a period of three years. At the time of printing, the IMB understands that 'marketed' means that at least one pack size of any presentation of a product must be released into the distribution chain. By 'product' is meant any product with the same active substance(s) and (root) name from the same authorisation holder. However final clarification on this issue will only be available when Chapter I of the Notice to Applicants is published by the EU Commission.

Authorisations granted before 30 October 2005: for these products, a presumption will be made that the product is marketed. Authorisation holders should inform the IMB after 30 October 2005 if this is not the case or whenever the product ceases to be marketed, even temporarily.

Authorisations granted after 30 October 2005: authorisation holders of products which are authorised after 30 October 2005 must inform the IMB when the product is marketed and whenever it ceases to be marketed, even temporarily. If no notice is given, it will be assumed that the product is not marketed.

When a product has not been 'marketed' for three years from 31 October 2005, the authorisation ceases to be valid and the IMB will proceed to revoke the authorisation.

When authorisations are transferred to a new authorisation holder, the new authorisation holder takes over the existing marketing status of the product. For example, if no presentation of a product was marketed for two years by the old authorisation holder, then the new authorisation holder has only one more year in which to market the product, regardless of whether or not he takes over all authorisations in the range.

A notification form is being drafted currently and will be made available by October 2005.

Homeopathic products

The new EU Directive, 2004/27/EC due to come into effect on 31 October 2005 applies to homeopathic medicinal products (HMPs). There are two particular changes to the legislation which should be taken into account when submitting applications for the registration scheme.

- Invented names are now permitted for complex HMPs. It should be noted however, that indications are not permissible in such invented names.
- The provision regarding Braille on the labelling applies to HMPs. Therefore complex products should include this on the labelling.

In line with the new EU Directive, Irish legislation relating to medicinal products is being reviewed and updated. The new legislation will be published in October 2005 and should be taken into account when submitting applications for the Simplified Registration Scheme.

Publication of marketing authorisations and SPCs

Under Article 21.3 of Directive 2004/27/EC, the IMB will be required to make the marketing authorisation and the SPC publicly available. It is intended to make publicly available the licence (cover) page of the authorisation schedule and the SPC. These documents will be made available on request, though it is intended to publish them on the IMB website in time.

Public availability of assessment reports

Under Article 21.4 of Directive 2004/27/EC, the IMB will be required to make the assessment report publicly available. The IMB intends to prepare a draft public assessment report for new nationally-authorised products and send it to the applicant for comment. The final report will be made publicly available. It will be updated whenever information important for the quality, safety or efficacy of the product is submitted.

In the case of mutual-recognised products, the Reference Member State will be responsible for preparing the public assessment report and making it available in accordance with procedures to be defined by the Co-ordination Group for Mutual Recognition and Decentralised Procedures.

Pharmacovigilance

Arising from the revised legislation, the following provisions will apply:

- *Pharmacovigilance Systems*
  In addition to existing requirements to notify competent authorities of the Qualified Person for pharmacovigilance, from 1 November 2005, all applications for marketing authorisations must include a detailed description of the pharmacovigilance system, and where appropriate, the risk management system used by the MAH. A guideline on Risk Management Systems for Medicinal Products for Human Use is currently in development at EU level and will be released for consultation shortly.

- *Suspected Transmission of Infectious Agents*
  The MAH will be required to submit all suspected serious unexpected adverse reactions and any suspected transmission via a medicinal product occurring in a third country. A guideline on Reporting of Suspected Transmission of Any Infectious Agent Via a Medicinal Product is currently in development at EU level and is expected to be released for consultation by the EMEA in July 2005.

- *Electronic ADR Reporting*
  Mandatory electronic reporting applies to products authorised through the centralised, mutual recognition and national authorisation procedures. Companies may choose to submit relevant Individual Case Safety Reports (ICSRs) either through the EudraVigilance Gateway follow-

ing completion of a satisfactory testing programme, or via the EVWeb interface. Any company intending to submit reports electronically via EudraVigilance and who has not as yet contacted the IMB indicating their readiness for testing should do so (Ms. Shirley Mulvey at **shirley.mulvey@imb.ie**) for further information and testing details.

The IMB is actively testing electronic submission of ICSRs with the EMEA and hopes to complete testing and move to the production phase with EudraVigilance shortly. In accordance with the revised legislation, the IMB will submit suspected serious adverse reactions occurring in Ireland to the agency via EudraVigilance.

Companies are requested to continue providing paper copies of the reports during the initial stages of this process. The IMB will notify companies when we are ready to accept 'electronic only' versions of the reports.

Further information on electronic reporting is available in Part III – EU Electronic Exchange of Pharmacovigilance Information - Volume 9 of The Rules Governing Medicinal Products in the European Union – Pharmacovigilance-Medicinal Products for Human and Veterinary Use.

- *Periodic Safety Update Reports (PSURs)*

The submission cycle for PSURs has been amended. Following the initial placing of a product on the market, PSURs shall be submitted immediately upon request or at the following intervals: 6-monthly for the first 2 years; annually for the subsequent 2 years; and, thereafter, at three-yearly intervals.

- *Pharmacovigilance Inspections*

A defined legal basis for pharmacovigilance inspections has been established. Such inspections will be carried out on a routine basis as well as 'for cause'. A guideline on Monitoring of Compliance with Pharmacovigilance Regulatory Obligations and Pharmacovigilance Inspections is currently in development at EU level and will be released for consultation shortly.

- *Publication of Pharmacovigilance Data*

The IMB will make anonymised ADR data publicly available.

Directive 2001/83/EC, as amended by Directive 2004/27/EC, may be viewed at http://pharmacos.eudra.org/F2/eudralex/vol-1/home.htm. Marketing Authorisation Holders are advised to be aware of all of their legal obligations relating to pharmacovigilance as detailed in that document. It should be noted that Volume 9 of The Rules Governing Medicinal Products in the European Union – Pharmacovigilance - Medicinal Products for Human Use and Veterinary Medicinal Products, has been revised to take into account of the changes to the legislation relating to MAH pharmacovigilance activities. The revised guideline is expected to be issued for consultation by the EU Commission shortly.

HERBAL MEDICINES

The Directive on Traditional Herbal Medicinal Products (2004/24/EC) was published in the Official Journal of the European Union (Ref: OJ L 136, 30.04.2004, p. 85) and so came into force on 30 April 2004. This new Directive is due to be transposed into Irish national law by the Department of Health and Children by 30 October of this year.

The Department of Health and Children has formally requested that the IMB take responsibility for this legislation in line with its remit for the licensing of the manufacture, preparation, importation, distribution and sale of medicinal products for human use. Therefore, in compliance with Article 2.1 of this legislation, the IMB will have a traditional herbal registration scheme in place by 30 October 2005 and be ready to assess and, where appropriate, grant registration through national and European procedures as appropriate.

The purpose of the Traditional Herbal Medicinal Products Directive is to harmonise the legislative framework for marketing traditional herbal medicinal products within the European Community. This Directive introduces a simplified registration procedure that gives herbal medicinal products recognition and enhanced status, while ensuring protection of public health. Directive 2004/24/EC states that all eligible herbal medicinal products placed on the Irish market must be registered under this scheme. It must be noted, however, that this Directive does not affect products classified as prescription-only medicines under the Medicinal Products (Prescription Control and Supply) Regulations 2003.

Existing products on the Irish market on 30 April 2004 that fall within the scope of the Traditional Herbal Medicinal Products Directive obtain a transitional period of seven years within to comply with the requirements of the new Directive. The Directive requires this transitional period to end by 30 April 2011.

The IMB has established a project team to oversee the implementation of Directive 2004/24/EC. This team is currently developing implementation plans, which will include guidance on particular sections of the legislation. As soon as such guidance is available, including any received from the European Commission, the IMB will make it available on the IMB web site. As part of the implementation process, the IMB has established a voluntary pre-application notification scheme, where members of the herbal industry are invited to inform the IMB of products that will qualify for registration in accordance with the Directive. The voluntary pre- application notification scheme will allow the IMB to conduct registration effectively, enable the IMB to work with those operating within the herbal medicine sector and help identify those products that will benefit from the seven-year transition period. Details of this scheme will be sent directly to all interested parties and will be available on the IMB website.

Any queries can be sent via e-mail to **herbalmedicines@imb.ie**.

HOMEOPATHIC MEDICINES

Simplified Registration Scheme (SRS) for complex HMPs

The IMB is continuing the registration of homeopathic medicinal products as outlined in previous issues of the Newsletter with the launch of the final phase of the SRS. Applications to register complex homeopathic medicinal products will be accepted by the IMB from 1 November 2005. The following notice will appear in the *Irish Times* on 1 October 2005.

Medicinal Products (Licensing and Sale) Regulations, Statutory Instrument Number 142 of 1998: Simplified Registration Scheme for Homeopathic Medicinal Products for Human use.

Companies who wish to market Complex Homeopathic Medicinal Products, which qualify for the Simplified Registration Scheme, as provided for in the above regulations and in accordance with EU Directives for Human Medicines, 92/73/EEC, 2001/83/EC and 2004/27/EC; are hereby notified that applications for such registration can be submitted to the IMB with effect from the 1st of November 2005.

All applications for complex products, containing a number of different substances, in homeopathic dilution, must be submitted to the IMB between 1/11/2005 and 31/5/2006, in order that such products may lawfully remain on the market.

Any product in the complex category for which an application has not been submitted by the date above must be removed from the market by 31/8/2006.

Guidance Notes and Application Forms for the scheme are available directly from the IMB or on the web site at: (www.imb.ie).

Deadline for Single Animal Product Applications.

It should be noted that the deadline (30 April 2005) for submission of applications to register single animal products has now passed. Single animal products, for which a registration application has not been received by the IMB, can no longer remain lawfully on the market.

European Directorate for the Quality of Medicines (EDQM).

EDQM has published the Proceedings of their Symposium titled: 'Quality of Homeopathic Products in the New European Legislative Framework', held in February 2005. These, along with slides of the presentations, can be viewed on: (**www.pheur.org**).



VETERINARY MEDICINES

LEGISLATION AND GUIDELINES

The following European guidelines have been adopted

CVMP Guideline on a Strategy for Triggering Investigations preceding Regulatory Actions by EU Competent Authorities (EMEA/CVMP/ 900/03-Post Consultation). Comes into effect 1st November 2005.

VICH GL28: Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing (CVMP/VICH/645/01-Rev.1-FINAL). For implementation in March 2006.

Guideline on plastic immediate packaging materials (EMEA/CVMP/205/04). This joint Human / Veterinary guideline was maintained with a difference in the annex (human CTD format, vet non-CTD format). Comes into effect on 1 December 2005.

Guideline on stability testing for applications for variations to a marketing authorisation (EMEA/CVMP/373/04). Comes into effect on 1 December 2005.

European reporting form for veterinarians and veterinary health professionals (EMEA/CVMP/893/04-POST-CONSULTATION-Rev.1). Comes into effect on 15th December 2005.

VETERINARY INFORMATION DAY 2006

We are planning to hold a Veterinary Information Day in Quarter 2 of 2006. If you have any topics of interest you would like to have discussed, please email **vetinfo @imb.ie** .

NEW MEDICINES LEGISLATION DIRECTIVE 2004/28/EC

The guidance below is based on the IMB's current understanding of the new requirements, which are the subject of on-going discussion at EU level. Arising from these discussions, existing EU guidance documents and forms are undergoing revision

and new documents are being drafted. Companies are advised to check the EMEA, EU Commission, and VMRFG websites regularly over the coming months for updates and further information. Further IMB guidance will be published when these discussions have concluded and EU guidance and forms are published.

The guidance below applies to nationally-authorised products. For products within mutual-recognition, please also see the guidance on the VMRFG website. For products authorised via the centralised procedure, please see the guidance on the EMEA website.

New applications for authorisations

All new applications submitted to the IMB after 30 October 2005 for a national authorisation or through the mutual-recognition or decentralised procedures must comply with the new requirements. Applicants should ensure that they submit the required information in line with updates given on the EU Commission and VMRFG websites.

Applications for variations to existing authorisation

The general procedures for variations are not affected by the new medicines legislation. However specific guidance may be provided for particular variations which may be affected by the new requirements. Applicants should ensure they have the latest information from the EU Commission's website and the website of the VMRFG.

Article 27 of Directive 2004/28/EC requires the authorisation holder to submit any new information which might amend the application documents, any information on prohibitions or restrictions in another country and any new information which might influence the benefits and risks of the product. All such information must be submitted as a variation application.

Renewals of existing marketing authorisations

The IMB's requirements in relation to renewals of product authorisations for medicinal products for veterinary use are outlined below. In essence, the IMB will require one further renewal under the new directive for all existing authorisations. Specific details are given below for authorisations falling into different categories.

Authorisations which have an expiry date before or on 30 October 2005

Applications should be made according to the current requirements outlined in the IMB website (**www.imb.ie**). The renewed authorisations will be issued under the current legislation and will be valid for a five-year period. These authorisations will undergo a further renewal under the new legislation by 30 October 2010.

Authorisations which have an expiry date after 30 October 2005

- *Timing*
  Applications for authorisations which are due for renewal between 31 October 2005 and 30 April 2006 should be submitted at least three months in advance. Applications for authorisations which are due for renewal from 1 May 2006 must be submitted six months before the expiry date.

- *Applications*
  Applications must include the EU renewal application form and the IMB form for additional national requirements, and all documents required by these forms. Both forms will be updated in line with the new requirements. At the time of printing, the IMB does not have an expected date of revision for the EU form; the IMB form will be revised once the revised EU form is available. Applicants should continue to use the current forms until such time as the new forms are published. The following requirements should also be noted:
  - Periodic Safety Update Reports are an integral part of the renewal process and will continue to be required in support of renewal applications.
  - Under Article 50f of Directive 2004/28/EC, manufacturers of finished products are obliged to use active substances made under conditions of GMP. The renewal application must include declarations that the active substance manufacturer(s) operate in compliance with the detailed guidance on GMP for starting materials. Further guidance on the declarations is awaited from the relevant EU working parties.

- *Renewed authorisations*
  The renewed authorisation will be valid for an indefinite period. However a second renewal may be required for pharmacovigilance reasons. In these cases, the renewed authorisation will be valid for a five-year period.

Product information (SPC, label and leaflet)

The new legislation includes changes to:

- format and content of the SPC
- content of labels
- content and format of package leaflets
- package leaflets written in terms comprehensible for the general public

Authorisations granted before 30 October 2005

Products which are currently authorised should comply with the new requirements by 30 October 2010 at the latest. The update may be done at the time of renewal of the product authorisation (so long as the changes are clearly outlined in the application) or by the submission of a variation application.

Authorisations granted after 30 October 2005

New products authorised after 30 October 2005 must comply with the new requirements for the SPC, label and leaflet.

Additional guidance on change in format of the SPC

Authorisations issued after 30 October 2005 will be issued in accordance with the new SPC format. Updating of the SPC Guideline is currently underway and the updated guideline will be available on the European

Commission website (**http://pharmacos.eudra.org**/) when finalised.

To assist applicants in the timely processing of applications which include updating of the SPC format, the IMB requests that, in addition to the paper copy documents submitted in support of the application, applicants submit the SPC in the required new format by email to the following address: **vetspcs@imb.ie**. The cover letter should clearly indicate the name of the product, the VPA number and the procedure to which the SPC relates. SPCs submitted by e-mail must not include any changes apart from those associated with the reformatting and, in the case of SPCs submitted with other variation applications, any proposed SPC changes relevant to that variation. The latter changes should be highlighted. Applicants are requested to follow the conventions for IMB SPC templates as outlined on the IMB website or use the new SPC template which will be provided on the IMB website (**www.imb.ie**) when finalised by the Notice to Applicants.

Finally, applicants should be aware that, in respect of those authorisations issued under Directive 2004/28/EC, the SPCs will include information on the excipient content and that SPCs will be published in full on the IMB website of authorised veterinary medicinal products.

Sunset clause

The sunset clause (Article 28.4 of Directive 2004/28/EC) will be applied to all products after 30 October 2005. Under these provisions, a product authorisation ceases to be valid if the product has not been marketed for a period of three years. At the time of printing, the IMB understands that 'marketed' means that at least one pack size of any presentation of a product must be released into the distribution chain. By 'product' is meant any product with the same active substance(s) and (root) name from the same authorisation holder. However final clarification on this issue will only be available when Chapter I of the Notice to Applicants is published by the EU Commission.

Authorisations granted before 30 October 2005: for these products, a presumption will be made that the product is marketed. Authorisation holders should inform the IMB after 30 October 2005 if this is not the case or whenever the product ceases to be marketed, even temporarily.

Authorisations granted after 30 October 2005: authorisation holders of products which are authorised after 30 October 2005 must inform the IMB when the product is marketed and whenever it ceases to be marketed, even temporarily. If no notice is given, it will be assumed that the product is not marketed.

When a product has not been 'marketed' for three years from 31 October 2005, the authorisation ceases to be valid and the IMB will proceed to revoke the authorisation.

When authorisations are transferred to a new authorisation holder, the new authorisation holder takes over the existing marketing status of the product. For example, if no presentation of a product was marketed for two years by the old authorisation holder, then the new authorisation holder has only one more year in which to market the product, regardless of whether or not he takes over all authorisations in the range.

A notification form is being drafted currently and will be made available by October 2005.

Homeopathic products

Provisions for registration of homeopathic veterinary medicinal products are amended by Directive 2004/28/EC and will be reflected in the revised Irish legislation relating to Animal Remedies which is being prepared by the Department of Agriculture and Food. Guidance will be provided on the IMB website by 30 October 2005.

Publication of marketing authorisations and SPCs

Under Article 25.3 of Directive 2004/28/EC, the IMB will be required to make the marketing authorisation and the SPC publicly available.

It is intended to make publicly available the licence (cover) page of the authorisation schedule and the SPC. The SPC will be published on the IMB website.

Public availability of assessment reports

Under Article 25.4 of Directive 2004/28/EC, the IMB will be required to make the assessment report publicly available. The IMB intends to prepare a draft public assessment report for new nationally-authorised products and send it to the applicant for comment. The final report will be made publicly available. It will be updated whenever information important for the quality, safety or efficacy of the product is submitted.

In the case of mutual-recognised products, the Reference Member State will be responsible for preparing the public assessment report and making it available in accordance with procedures to be defined by the Co-ordination Group for Mutual Recognition and Decentralised Procedures.

Pharmacovigilance

Arising from the revised legislation, the following provisions will apply:

- *Pharmacovigilance Systems*
  In addition to existing requirements to notify competent authorities of the Qualified Person for pharmacovigilance, from 1 November 2005, all applications for marketing authorisations must include a detailed description of the pharmacovigilance system.

- *Suspected Transmission of Infectious Agents*
  The MAH will be required to submit all suspected serious unexpected adverse reactions and any suspected transmission via a medicinal product occurring in a third country. A guideline on Reporting of Suspected Transmission of Any Infectious Agent Via a Medicinal Product is currently in development at EU level and is expected to be released for consultation by the EMEA in July 2005.

- *Electronic ADR Reporting*
  In accordance with Article 75 (1) of the amended Directive, it is required that the MAH, save in exceptional circumstances, submit reports of suspected adverse reactions electronically. Electronic reporting applies to products authorised through the Centralised, Mutual Recognition and National authorisation procedures. The system for the elec-

tronic submission of adverse reaction reports developed by the EMEA in close consultation with the Member States, the Commission and with support from veterinary pharmaceutical industry organisations is called EudraVigilance Veterinary and may be accessed at **http://eudravigilance.emea.eu.int/veterinary.** Companies may choose to submit relevant individual adverse reaction reports either through the EudraVigilance Gateway, following completion of a satisfactory testing programme, or via the EVWeb interface. You are invited to visit the website and read the general information on EudraVigilance and explanations of different methods of reporting into the system. While electronic reporting is preferred, non-electronic reporting (paper copy) may be considered acceptable for certain authorisation holders where the anticipated number of annual reports is expected to be low. If, after visiting the Eudravigilance website, you would like further information on electronic reporting you are invited to contact either the EMEA or the IMB.

Further information on electronic reporting is available in Part III – EU Electronic Exchange of Pharmacovigilance Information - Volume 9 of The Rules Governing Medicinal Products in the European Union – Pharmacovigilance - Medicinal Products for Human and Veterinary Use.

- *Periodic Safety Update Reports (PSURs)*
  The submission cycle for PSURs has been amended. Following the initial placing of a product on the market, PSURs shall be submitted immediately upon request or at the following intervals: 6-monthly for the first 2 years; annually for the subsequent 2 years; and, thereafter, at three-yearly intervals.

- *Pharmacovigilance Inspections*
  A defined legal basis for pharmacovigilance inspections has been established. Such inspections will be carried out on a routine basis as well as 'for cause'. A guideline on Monitoring of Compliance with Pharmacovigilance Regulatory Obligations and Pharmacovigilance Inspections is currently in development at EU level and will be released for consultation shortly.

- *Publication of Pharmacovigilance Data*
  The IMB will make anonymised ADR data publicly available.

Directive 2001/82/EC, as amended by Directive 2004/28/EC, may be viewed at **http://pharmacos.eudra.org/F2/eudralex/vol-5/home.htm**. Marketing Authorisation Holders are advised to be aware of all of their legal obligations relating to pharmacovigilance as detailed in the directive. It should be noted that Volume 9 of The Rules Governing Medicinal Products in the European Union - Pharmacovigilance - Medicinal Products for Human Use and Veterinary Medicinal Products, has been revised to take into account of the changes to the legislation relating to MAH pharmacovigilance activities. The revised guideline is expected to be issued for consultation by the EU Commission shortly.

Veterinary medicinal products for horses

The European Commission has recently informed the IMB that, in accordance with Directive 2001/82/EC as amended by Directive 2004/28/EC, it is not permissible to authorise veterinary medicinal products for horses that may be slaughtered for human consumption, other than those containing active substances which are listed in Annexes I, II or III of Council Regulation (EEC) 2377/90. The Commission has also informed the IMB that, in accordance with Article 6(3) of Directive 2001/82/EC, the IMB may authorise a veterinary medicinal product containing pharmacologically active substances not included in Annexes I, II or III of Council Regulation (EEC) No. 2377/90, for horses that have been declared as not being intended for slaughter for human consumption. However, the IMB is **not permitted** to authorise products containing substances that appear in Annex IV of the Regulation. The IMB is also **not permitted** to authorise such medicines for use in the treatment of conditions for which a veterinary medicinal product is already authorised for horses.

Any existing marketing authorisations for horses relating to substances not included in Annexes I, II or III for horses must therefore be withdrawn or amended. If an amendment application is chosen, it will be necessary to justify the nomination on the basis that there is no alternative authorised veterinary medicinal product for the treatment of the condition in horses (as stated on the indications for use in the Summary of Product Characteristics (SPC)). The target species indications for such products must be declared as 'Horses declared as not being intended for slaughter for human consumption' while the withdrawal period must be amended to 'Treated horses may never be slaughtered for human consumption'. The application will be considered by the IMB as a Type II complex variation application (fee code 596) with the applicable fee. On receipt of such applications, the IMB will evaluate the justification provided against its database of authorised veterinary medicinal products (available on **www.imb.ie**) before reaching any decision to accept the use of the product for horses declared as not being intended for human consumption.

COMMUNICATION AND CUSTOMER SERVICE SURVEY

The Veterinary Medicines Department is planning to initiate a Communication and Customer Service Survey. This survey is expected to be conducted during Summer 2005 by an independent third party. The survey is expected to provide benchmarks to enhance the services and communications provided by the department into the future. Your assistance in completing this questionnaire will be much appreciated.

CHANGE TO VETERINARY PRODUCT AUTHORISATION FORMAT (PHARMACEUTICALS)

The Veterinary Product Authorisation format has been amended to include the name and address of the manufacturer(s) of the active substance(s) in the product specific

details section of the document (Part II). This change has been applied to all new and renewed licences issued since 1 May 2005.

THE NIMBUS PROGRAMME

The IMB is currently working on expanding the NIMBUS electronic tracking programme for the management of the work flow of applications to the Veterinary Medicines Department. NIMBUS incorporates both organisational and technology changes for the department and will be implemented before the end of the year. All licensing applications will be managed through this new function with case managers responsible for tracking individual applications. Overall this new structure is designed to reflect the streamlining of licensing activities in the most effective and efficient use of resources to provide a quality service to all stakeholders. We appreciate your tolerance with any disruptions we might have in the roll out of NIMBUS to the Veterinary Medicines Department.

COMPLIANCE

COMPLIANCE DEVELOPMENT STUDY

The IMB has recently completed a development study in the Inspectorate and Enforcement Department. Growth in new activities together with imminent changes in legislation acted as the impetus for the study. As part of the process a number of external stakeholder bodies participated in the study and feedback was very positive. As anticipated it was recognised early in this process that staffing, management structure and business processes could be further enhanced to support the operation of the department and also to deliver improved services to stakeholders.

Various recommendations have now been made and approved by the IMB Board. These recommendations are currently being implemented as part of a comprehensive change programme in the newly titled Compliance Department.

As part of this process we are pleased to announce the appointment of a new five person Compliance Management Team reporting to Mr. John Lynch, Director of Compliance: Mr Hugo Bonar as Enforcement Manager, Ms Paula Byrne as Licensing Manager, Ms. Anne Hayes as Inspection Manager, Ms Yvonne Maloney as Planning Manager and Mr Kevin O'Donnell as Market Compliance Manager.

Updates on additional appointments to the department will be given over the coming months.

In keeping with the IMB's policy on continuous improvement, the redesign of the Compliance Department will be underpinned by additional resources to support new activities together with significant investment in information technology.

We would like to express our thanks to those stakeholders who provided valuable input into the development process and look forward to the benefits that the new departmental arrangements will bring.

UPDATE ON GMPS

Product Quality Reviews (PQRs) - Chapter 1

It is expected that Chapter 1 will be published in early September on the EU Commissions website **www./pharmacos.eudra.org/F2/home**

The intended date of coming into effect of this new requirement will be 1 January 2006. From this date onwards data should be collected for all products, including 'export only' products. To avoid having all Product Quality Reviews (PQRs) due on 1 January each year, PQR preparation may be staggered during 2006 to cover a shorter period of time. For example, a company could prepare a PQR for the period 1 January 2006 to 30 June 2006. Subsequent PQRs would be prepared to cover annual periods ending 30 June.

On-going stability - Chapter 6

It is expected that Chapter 6 will be published in early September on the EU Commissions website **www./pharmacos.eudra.org/F2/home**

By 1st January 2006, companies will be required to have an on-going stability programme in place. At least one batch per year of product manufactured in every strength and every primary packaging type, if relevant, should be placed on the stability programme (unless none are produced during that year). The principles of bracketing and matrixing designs may be applied if scientifically justified in the protocol.

It is intended that the stability protocols and reports will be reviewed by the IMB in the course of GMP inspections. Stability studies performed by contract laboratories may also be inspected at the site of the contract laboratories to verify compliance of the laboratories with GMP. Contract laboratories that are located outside the EU/EEA can be used.

It is currently intended that contract laboratories will be included on the Manufacturer's Licence. The Compliance Department will contact manufacturers at a later stage regarding this matter.

GMP requirements for active substances

From 30 October 2005 manufacturers of human and veterinary medicinal products will be required 'to comply with the principles and guidelines of good manufacturing practice for medicinal products and to use as starting materials only active substances, which have been manufactured in accordance with the detailed guidelines on good manufacturing practice for starting materials.'

Medicinal products, whose manufacture commences after 30 October 2005, may only be released to the market if the qualified person is assured that the active substance used

has been manufactured in accordance with good manufacturing practice.

ENVELOPES USED TO MAIL RECALL AND CAUTION-IN-USE LETTERS

The IMB would like to obtain the opinion of stakeholder groups (for example, marketing authorisation holders, industry representative bodies, manufacturers, primary distributors (who may sometimes execute recall actions on behalf of MAH companies) and health care professionals on the following proposal:

Proposal It is proposed that Recall and Caution in Use letters intended for addresses in Ireland be mailed in envelopes which carry a prominent message on the outside of the envelope which indicates that the letter contains either a Recall or a Caution in Use letter. It is proposed that a format for the envelope text would be defined by the IMB as guidance for industry for such envelopes. This format would then be published in a revised version of the IMB Guidance Note on Product Recalls.

Reason for this initiative In a recent recall action, at two different locations within Ireland, the envelopes containing the recall letters were not opened in a timely manner by those who received the letters. This significantly delayed the execution of the recall at those two locations. The use of flagged envelopes may have prevented this from occurring.

Advantages Flagged envelopes will alert the recipient in a busy hospital, pharmacy practice, etc, that the envelope contains an important communication and that it should be opened immediately. This should help to achieve a timely execution of recalls, and a timely follow-up on cautionary messages.

Marketing authorisation holders, manufacturers, primary distributors, and other stakeholder groups are invited to send any opinions on the above proposal to the IMB. These should be forwarded to Ms. Ann Harkin, Technical Officer in the IMB Compliance Department, via e-mail (ann.harkin@imb.ie) by 30 September, 2005.

Human New Product Authorisations Issued (January–June 2005)

PA Number	Product Name
PA0007/002/010	ATROVENT INHALER CFC-FREE
PA0043/006/009	NUROFEN 200 mg MELTLETS
PA0043/006/010	NUROFEN FOR CHILDREN MELTLETS
PA0298/014/001	Trimethoprim BP
PA0298/014/002	Trimethoprim BP
PA0417/016/004	HALIBORANGE EFFERVESCENT VITAMIN C
PA0476/017/001	CIPROFLOXACIN OLINKA
PA0476/017/002	CIPROFLOXACIN OLINKA
PA0476/017/003	CIPROFLOXACIN OLINKA
PA0476/017/004	CIPROFLOXACIN OLINKA
PA0568/002/003	COVERSYL
PA0711/009/005	DICLAC RELIEF
PA0899/020/001	ELTROXIN
PA1017/002/001	CETRINE
PA1017/002/002	CETRINE ALLERGY
PA1146/001/001	GABAPENTIN MASTERFARM
PA1146/001/002	GABAPENTIN MASTERFARM
PA1146/001/003	GABAPENTIN MASTERFARM
PPA0465/051/003A	KLACID LA
PPA0465/115/001A	FOSAMAX ONCE WEEKLY
PPA0465/124/001A	KLIOGEST
PPA0465/125/001A	CREON 10000
PPA0465/125/002A	CREON 25000
PPA0465/126/001A	DYAZIDE
PPA0465/128/001A	IDEOS
PPA0465/132/001A	DOVONEX
PPA0465/132/002A	DOVONEX
PPA0465/132/003A	DOVONEX SCALP
PPA0465/133/001A	NOLVADEX D
PPA0465/144/001A	CASODEX
PPA1151/001/002A	SINEMET
PPA1151/001/003A	SINEMET PLUS
PPA1151/003/001A	ZOTON
PPA1151/003/002A	ZOTON
PPA1151/005/001A	COZAAR
PPA1151/006/001A	SERETIDE 500
PA0022/065/007	EFEXOR XL
PA0043/041/001	STREPSILS EXTRA BLACKCURRANT
PA0046/060/008	Innohep 2,500
PA0046/060/009	Innohep 3,500
PA0046/060/010	Innohep 10,000
PA0046/060/011	Innohep 14,000
PA0050/062/008	Rocephin
PA0281/119/001	Ramil
PA0281/119/002	Ramil
PA0281/119/003	Ramil
PA0281/119/004	Ramil
PA0282/078/001	EQUORAL
PA0282/078/002	EQUORAL
PA0282/078/003	EQUORAL
PA0282/078/004	EQUORAL
PA0282/079/001	IPRAMOL STERI-NEBS
PA0436/008/010	SALBUTAMOL 100 CFC-FREE INHALER
PA0540/137/001	RAMIPRIL
PA0540/137/002	RAMIPRIL
PA0540/137/003	RAMIPRIL
PA0540/137/004	RAMIPRIL

continued on next page ▼

Human New Product Authorisations Issued (January–June 2005) cont.

PA Number	Product Name	PA Number	Product Name
PA0540/137/005	Ramipril	PA0968/002/002	KESTINE
PA0540/137/006	Ramipril	PA1031/001/001	DOXAZOSIN DISPHAR
PA0540/137/007	Ramipril	PA1031/001/002	DOXAZOSIN DISPHAR
PA0540/137/008	Ramipril	PA1031/001/003	DOXAZOSIN DISPHAR
PA0544/024/002	M-M-R II Measles Mumps & Rubella	PA1044/002/001	PROFLOXIN
	Live Attenuated	PA1044/002/002	PROFLOXIN
PA0577/069/001	Cifloxager	PA1044/002/003	PROFLOXIN
PA0577/069/002	Cifloxager	PA1077/042/006	Becotide Evohaler
PA0577/069/003	Cifloxager	PA1077/042/007	Becotide Evohaler
PA0584/003/001	BECLONEB	PA1077/042/008	Becotide Evohaler
PA0584/003/002	BECLONEB	PA1077/042/009	Becotide Evohaler
PA0584/004/001	BECLOSPIN	PA1097/001/001	Gabapentin
PA0584/004/002	BECLOSPIN	PA1097/001/002	Gabapentin
PA0618/041/001	PARACETAMOL/CAFFEINE/CODEINE	PA1097/001/003	Gabapentin
	AND DOXYLAMINE	PPA0465/033/003	Zantac 75
PA0678/012/008	AUGMENTIN 1000/62.5 mg Pro-	PPA0465/058/003	Zoton FasTab
	longed Release Film-Coat	PPA0465/058/004	Zoton FasTab
PA0810/001/006	LIPANTIL SUPRA	PPA0465/067/002	Coversyl
PA0895/005/001	DEXIMUNE	PPA0465/078/006	RISPERDAL
PA0895/005/002	DEXIMUNE	PPA0465/102/001A	SOTACOR
PA0895/005/003	DEXIMUNE	PPA0465/102/002A	SOTACOR
PA0895/006/001	CICLOSPORIN Dumex	PPA0465/120/001A	ELTROXIN
PA0895/006/002	CICLOSPORIN Dumex	PPA0465/120/002A	ELTROXIN
PA0895/006/003	CICLOSPORIN Dumex	PPA0465/122/001A	VASTAREL
PA0895/007/001	Ciclosporin Pharmachemie	PPA0465/127/002	Serevent Diskus
PA0895/007/002	Ciclosporin Pharmachemie	PPA0465/129/001A	LEXAPRO
PA0895/007/003	Ciclosporin Pharmachemie	PPA0465/129/002A	LEXAPRO
PA0895/008/001	Ciclosporin Genfarma	PPA0465/136/001A	NEORAL SOFT GELATIN
PA0895/008/002	Ciclosporin Genfarma	PPA0465/136/002A	NEORAL SOFT GELATIN
PA0895/008/003	Ciclosporin Genfarma	PPA0465/136/003A	NEORAL SOFT GELATIN
PA0915/009/001	Bytrite	PPA0465/138/001A	XATRAL
PA0915/009/002	Bytrite	PPA0465/138/002A	XATRAL
PA0915/009/003	Bytrite	PPA0465/140/001A	CRESTOR
PA0915/009/004	Bytrite	PPA0465/140/002A	CRESTOR
PA0934/003/001	Naltrexone	PPA0465/140/003A	CRESTOR
PA0966/007/001	BYZESTRA	PPA0465/143/001A	BETOPTIC
PA0966/007/002	BYZESTRA	PPA0465/145/001A	LEVONELLE
PA0966/007/003	BYZESTRA	PPA0465/148/001	Sinemet
PA0966/007/004	BYZESTRA	PPA0465/148/002	Sinemet
PA0966/008/001	BYFLUC	PPA0465/150/001	Rogaine Regular Strength
PA0966/008/002	BYFLUC	PPA1151/002/001A	LUSTRAL
PA0966/008/003	BYFLUC	PPA1151/002/002	Lustral

Human New Product Authorisations Withdrawn (January–June 2005)

PA Number	Product Name
PA0002/034/001	Pronestyl
PA0002/056/002	Staril
PA0002/056/003	Staril
PA0002/066/001	Stadol
PA0002/076/001	PACLITAXEL INJECTION CONCENTRATE
PA0003/004/001	Folex-350
PA0003/006/001	Guarem
PA0006/009/001	Sofra - Tulle
PA0007/002/001	ATROVENT METERED DOSE INHALER
PA0007/008/003	PERSANTIN - AMPOULES
PA0007/047/003	BONEFOS
PA0010/032/001	MONONINE FREEZE DRIED HUMAN COAG. FACTOR IX
PA0012/032/002	ULTRAPROCT
PA0013/040/003	Miacalcic Multidose Vials
PA0013/043/004	Sandostatin multi-dose
PA0013/090/001	AREDIA DRY POWDER
PA0019/033/004	GYNO TROSYL VAGINAL OVULES
PA0019/033/005	GYNO-TROSYL VAGINAL OVULES
PA0019/044/005	DIFLUCAN
PA0024/023/005	FLIXOTIDE ROTADISKS
PA0024/023/006	Flixotide Rotadisks
PA0024/023/007	Flixotide Rotadisks
PA0024/023/008	Flixotide Rotadisks
PA0030/013/001	Fabrol
PA0030/035/001	AllerEze
PA0035/014/002	DOLOBID
PA0035/014/004	Dolobid
PA0037/050/001	Artane
PA0037/050/002	Artane
PA0037/062/001	AUDICORT EAR
PA0038/078/001	Co-Brufen
PA0038/089/001	TARKA
PA0040/003/006	Flagyl
PA0040/003/009	Flagyl
PA0040/071/002	Nozinan
PA0046/004/004	Fucidin
PA0048/014/002	Ultracef
PA0057/005/003	Nuelin
PA0073/133/003	Vologen Retard
PA0100/033/001	SUSCARD BUCCAL
PA0100/033/004	SUSCARD BUCCAL
PA0100/037/001	Fletchers Enemette
PA0111/002/003	RIMACTANE
PA0126/080/001	Pericam 10
PA0126/080/002	Pericam 20
PA0141/020/001	VIVIOPTAL
PA0148/044/001	Vistalbalon
PA0167/111/001	BAXTER PROPOFOL
PA0167/111/002	BAXTER PROPOFOL
PA0172/030/001	Fibercon
PA0179/039/001	Aminoplasmal
PA0179/040/001	Aminoplasmal - E
PA0184/007/001	Mrs Cullens
PA0185/013/001	Verucasep
PA0185/015/001	Dynese Antacid
PA0185/021/001	Expulin Dry Cough Paediatric
PA0185/021/002	Expulin Dry Cough
PA0185/023/001	Galenamet
PA0185/023/002	Galenamet
PA0185/023/003	Galenamet
PA0185/025/002	Kapake Insts 30/500
PA0185/025/003	Kapake Insts 60/1000
PA0185/029/001	Minogal
PA0185/029/002	Minogal
PA0185/030/001	DF 118
PA0185/033/001	Clinimycin
PA0185/037/001	AILAX
PA0185/037/002	AILAX FORTE
PA0187/055/001	OCTONATIV-M
PA0187/055/002	OCTONATIV M
PA0212/008/001	TETABULIN
PA0258/001/001	ULC-AID Mouth Ulcer
PA0258/003/001	ULC-AID Mouth Ulcer Throat
PA0258/004/001	Tyrocane Throat
PA0258/005/001	PARACETAMOL B.P.
PA0258/007/001	Cupal
PA0258/009/001	Burnaid
PA0258/011/001	Cupal Cold/Flu with Cough Suppressant
PA0258/013/001	Verruca Treatment
PA0258/017/001	JUNIOR KAO-C DIARRHOEA
PA0258/017/002	ADULT KAO-C DIARRHOEA
PA0258/020/001	BRONALIN EXPECTORANT
PA0258/026/002	Junior Meltus
PA0258/031/001	Gluco-Lyte
PA0258/033/001	Tyrocane Junior Antiseptic
PA0258/034/001	Cystoleve Sachets
PA0258/035/001	Wapeze Insect Bite
PA0258/036/001	Cold Sore Lotion
PA0258/039/001	Cupal Decongestant Inhalent
PA0258/042/001	Novasil Plus Antacid
PA0258/043/001	Glycerin Lemon & Honey

continued on next page ▼

Human New Product Authorisations Withdrawn (January–June 2005) cont.

PA Number	Product Name
PA0281/044/002	Pinalgesic
PA0281/054/001	Pinamet Cimetidine
PA0281/071/001	Cortopin Hydrocortisone B.P.
PA0281/081/001	Amoxicillin Mixture
PA0281/081/002	Amoxicillin
PA0281/092/001	Pinamet
PA0281/094/001	Trimopan (Suspension)
PA0282/063/002	Serenace ampoules
PA0282/066/001	Sulpiride
PA0285/004/002	METRODIN HIGH PURITY /0.9% NACL
PA0285/004/003	METRODIN HIGH PURITY/0.9% NACL
PA0290/058/002	Isopto Carpine 1.0%
PA0290/058/003	Isopto Carpine 2.0%
PA0290/058/005	Isopto Carpine 4.0%
PA0436/021/006	Beclazone Easi-Breathe Inhaler
PA0436/021/007	Beclazone Easi-Breathe Inhaler
PA0436/021/008	Beclazone Easi-Breathe Inhaler
PA0436/029/001	Salamol Easi-Breathe Inhaler
PA0437/024/001	Naloxone Hydrochloride
PA0476/001/001	Exartin
PA0476/006/001	Paracetamol Infant
PA0483/004/001	Sterets Chlorhexidine
PA0522/009/001	High Potency Vitamin C
PA0540/019/001	MERBENTYL SYRUP
PA0544/001/001	Adsorbed Tetanus
PA0544/020/003	Measles Rubella Vaccine Live - syringe
PA0544/022/001	Attenuvax Vaccine
PA0544/025/001	Meruvax II Vaccine
PA0544/026/001	Mumpsvax Vaccine
PA0544/030/001	PNEUMO 23
PA0549/010/001	Fenofibrate Ethypharm
PA0549/010/002	Fenofibrate Ethypharm
PA0566/019/006	INTRALIPID 30%
PA0566/019/008	INTRALIPID 30%
PA0566/019/009	INTRALIPID 30%
PA0577/025/001	Laxol
PA0610/007/001	PRIPSEN
PA0610/009/001	Vitathone Chilblain
PA0610/010/001	GASTROCOTE
PA0610/016/001	Setlers Antacid Peppermint
PA0610/016/002	Setlers Antacid Spearmint
PA0667/001/001	Replens
PA0669/004/001	OCTEGRA
PA0669/004/002	OCTEGRA
PA0669/004/003	OCTEGRA
PA0677/012/001	Gallium Citrate

PA Number	Product Name
PA0678/078/001	ALPHOSYL
PA0678/081/001	Alphosyl
PA0678/081/002	Alphosyl Lotion
PA0678/087/001	ALPHOSYL HC
PA0692/001/001	Hacks Original
PA0692/001/002	Hacks Blackcurrant
PA0692/001/003	Hacks Honey & Lemon
PA0711/041/001	Fenor
PA0711/041/002	Fenor
PA0711/045/001	Orabet
PA0711/045/002	ORABET
PA0736/009/001	Nutriflex plus without electrolytes
PA0736/010/001	Nutriflex special without electrolytes
PA0748/008/002	Evorel Sequi
PA0748/011/005	Prepulsid
PA0748/011/006	Prepulsid Paediatric
PA0748/011/007	Prepulsid
PA0748/011/008	Prepulsid
PA0749/003/001	Methotrexate INJ Ampoules
PA0749/003/004	METHOTREXATE INJ VIALS
PA0757/002/001	Plesmet
PA0789/008/001	Alpharubicin
PA0789/009/001	Betarubicin
PA0789/010/001	Ebedox
PA0809/001/001	Fluoro-Uracil Roche Ampoules
PA0856/008/001	Lentizol
PA0856/008/002	Lentizol
PA0913/010/001	Flexin Continus
PA0913/010/002	Flexin Continus
PA0913/010/003	Flexin Continus
PA0935/001/001	FSME-IMMUN
PA0936/054/001	Euhypnos Elixir
PA0936/090/001	Reboxetine
PA0936/090/002	Reboxetine
PA0950/001/002	Antepsin
PA0970/001/002	ACCOLATE
PA0970/023/005	Zestril
PA1027/001/001	WINRHO SDF
PA1027/001/002	WINRHO SDF
PA1056/001/001	Psorin Scalp
PA1056/002/001	Psorin
PA1077/040/001	Becodisks
PA1077/040/002	Becodisks
PA1077/048/001	Ventodisks
PA1077/048/002	Ventodisks

Human New Product Authorisations (Mutual Recognition) (January–June 2005)

PA Number	Product Name
PA0013/113/001	BENTIFEN
PA0013/113/002	BENTIFEN SINGLE DOSE UNIT
PA0021/054/001	CanOral
PA0038/090/001	Zemplar
PA0062/044/001	Omnexel
PA0100/001/007	Colomycin Injection 500,000 Units
PA0100/001/008	Colomycin Injection 1,000,000 Units
PA0100/001/009	Colomycin Injection 2,000,000 Units
PA0108/027/001	TEVETEN PLUS
PA0126/136/001	Clonocid
PA0126/136/002	Clonocid
PA0126/136/003	Clonocid
PA0126/136/004	Clonocid
PA0126/139/001	Meloxicam
PA0126/139/002	Meloxicam
PA0167/121/001	Subcuvia
PA0170/021/001	Actonel Combi
PA0281/121/001	Lusert
PA0281/121/002	Lusert
PA0408/061/001	Citalopram
PA0408/061/002	Citalopram
PA0408/061/003	Citalopram
PA0436/038/001	Fungafine
PA0436/039/001	Myostin
PA0436/039/002	Myostin
PA0437/052/001	Paclitaxel
PA0566/002/004	AMINOVEN 8
PA0566/002/005	AMINOVEN 16
PA0566/002/006	AMINOVEN 25
PA0566/030/001	HARTMANN'S SOLUTION FOR INFUSION, PVC bag
PA0566/030/002	HARTMANN'S SOLUTION FOR INFUSION, PSEB bag
PA0566/030/003	HARTMANN'S SOLUTION FOR INFUSION, PPC PSEB bag
PA0566/030/004	HARTMANN'S SOLUTION FOR INFUSION, glass bottle
PA0566/036/001	Fresenius Propoven 1%
PA0566/036/002	Fresenius Propoven 1%
PA0566/036/003	Fresenius Propoven 2%
PA0577/046/003	Histaclar Syrup
PA0577/055/001	Zesger Plus 10
PA0577/055/002	Zesger Plus 20
PA0577/063/001	Pergolide
PA0577/063/002	Pergolide
PA0577/063/003	Pergolide
PA0577/065/001	Razolager
PA0577/065/002	Razolager
PA0577/066/001	Azromax
PA0577/066/002	Azromax
PA0577/068/001	Nailderm
PA0585/017/001	Lopraz
PA0585/017/002	Lopraz
PA0585/017/003	Lopraz
PA0585/019/001	Cholstat
PA0585/019/002	Cholstat
PA0585/019/003	Cholstat
PA0585/021/001	Emital
PA0585/021/002	Emital
PA0678/099/001	NIQUITIN CQ
PA0678/099/002	NIQUITIN CQ
PA0689/003/001	Foznol
PA0689/003/002	Foznol
PA0689/003/003	Foznol
PA0689/003/004	Foznol
PA0711/050/004	Sivatin
PA0711/057/005	FLUCOL
PA0711/057/006	FLUCOL
PA0711/057/007	FLUCOL
PA0711/065/001	Serlan
PA0711/065/002	Serlan
PA0711/067/001	Lanzol
PA0711/067/002	Lanzol
PA0711/068/001	Ondansetron
PA0711/069/001	Onton
PA0711/070/001	Fental
PA0711/070/002	Fental
PA0711/070/003	Fental
PA0711/070/004	Fental
PA0711/071/001	Ternaf
PA0711/071/002	Ternaf
PA0711/073/001	Fintrid
PA0749/008/001	Quinapril
PA0749/008/002	Quinapril
PA0749/008/003	Quinapril
PA0749/008/004	Quinapril
PA0749/009/001	Ondansetron
PA0749/009/002	Ondansetron
PA0789/013/001	Etoposid "Ebewe"
PA0798/003/001	Ditebooster
PA0800/004/001	Vivaglobin
PA0800/004/002	Vivaglobin
PA0865/012/001	Zofenil Plus
PA0865/013/001	Bifril Plus
PA0869/005/001	Testim

continued on next page

Human New Product Authorisations (Mutual Recognition) (January–June 2005) cont.

PA Number	Product Name
PA0913/024/001	BuTrans
PA0913/024/002	BuTrans
PA0913/024/003	BuTrans
PA0919/004/002	Menjugate
PA0959/001/002	TANTUM VERDE
PA0966/014/001	Bystat
PA0966/014/002	Bystat
PA0966/014/003	Bystat
PA0966/015/001	BySec
PA0966/015/002	BySec
PA0967/004/001	SERTRALINE 50mg Film-Coated Tablets
PA0967/004/002	SERTRALINE 100mg Film-Coated Tablets
PA0969/005/001	Triregol
PA1027/002/001	WinRho SDF
PA1027/002/002	WinRho SDF
PA1027/002/003	WinRho SDF
PA1058/001/002	ASCAL

PA Number	Product Name
PA1063/017/001	Citalopram
PA1063/017/002	Citalopram
PA1063/018/003	Lanafine
PA1100/002/001	Alvesco Inhaler
PA1100/002/002	Alvesco Inhaler
PA1100/002/003	Alvesco Inhaler
PA1147/002/001	Pravat
PA1147/002/002	Pravat
PA1147/002/003	Pravat
PA1159/001/002	Eucerin Intensive 10% w/w Urea Treatment Lotion
PA1167/001/001	Moxcipam
PA1167/001/002	Moxcipam
PA1177/001/001	ICG-Pulsion Powder for Solution for Injection
PA1177/001/002	ICG-Pulsion Powder for Solution for Injection
PA1183/001/001	Lithium Chloride
PA1228/001/001	Striant SR Mucoadhesive

Veterinary New Product Authorisations Issued (January–June 2005)

VPA Number	Product Name
10960/058/001	OVIMEC SHEEP DRENCH 0.08% W/V ABAMECTIN ORAL SOLN
10850/006/001	VIRBAMEC FOR CATTLE SWINE AND SHEEP 1%W/V
10879/021/001	ANISEC INJECTION
10879/023/001	CHANIJECT INJECTION
10879/024/001	SUMIJECT INJECTION
10879/028/001	MEDIMEC SOLUTION FOR INJECTION
10879/029/001	VETIMEC INJECTION

VPA Number	Product Name
10960/057/001	COMBIZOLE ORAL SUSPENSION
10879/022/001	ANIJECT INJECTION
10987/063/001	QUANIFEN CAT AND DOG
10987/062/001	QUENAZOLE CAT AND DOG
10879/030/001	ANISEC POUR-ON SOLUTION 0.5% W/V
10879/031/001	TOPIMEC POUR-ON SOLUTION 0.5% W/V

Veterinary New Authorisation Issued (Mutual Recognition) (January–June 2005)

VPA Number	Product Name
10857/068/001	EQVALAN DUO ORAL PASTE

VPA Number	Product Name
10007/028/001H	BIVATOP 200

Veterinary Product Authorisations Withdrawn ((January–June 2005)

VPA Number	Product Name
10019/016/001	PARATECT FLEX SUSTAINED RELEASE BOLUS
10277/002/001	FINADYNE FOR DOGS
10277/003/001	FINADYNE
10277/003/002	FINADYNE
10277/046/001	ZAQUILAN 60MG TABLETS FOR DOGS

VPA Number	Product Name
10277/046/002	ZAQUILAN 600MG TABLETS FOR DOGS
10277/056/001	REPIDOSE FIRST GRAZER
10835/008/001	PROGRAM PLUS
10835/008/002	PROGRAM PLUS
10835/008/003	PROGRAM PLUS

continued on next page ▼

Veterinary Product Authorisations Withdrawn (January–June 2005) cont.

VPA Number	Product Name	VPA Number	Product Name
10835/008/004	PROGRAM PLUS	10996/015/001	NYMFALON
10857/011/001	KETOFEN	10996/033/001	ENGEMYCIN 5% SOLUTION FOR INJECTION
10857/011/002	KETOFEN	10996/075/001	AMFIPEN 15%
10953/002/001	AUROFAC 20	10996/107/001	HOSTACYCLINE L.A.
10996/010/001	METRIJET 1500 SOLUTION FOR INFUSION	10999/072/001	NOROPROST

Veterinary Immunological New Authorisations Issued (January–June 2005)

VPA Number	Product Name	VPA Number	Product Name
10277/088/001	Covexin 10	10996/183/001	Lactovac
10019/103/001	Rispoval – BRSV – Pi3 – BVD	10996/184/001	Bovilis Ringvac
10019/104/001	PregSure BVD	10996/187/001	Nobilis ND C2
10996/182/001	Nobivac Ducat	10996/190/001	Nobilis Rhino CV

Veterinary Immunological Review Authorisations Issued (January–June 2005)

VPA Number	Product Name	VPA Number	Product Name
10277/060/001	Covexin 8	10996/130/001	Nobilis AE 1143
10277/063/001	Blackleg	10996/166/001	Nobivac DHPPI
10277/065/001	Tribovax T		